Recently, a HER2 discordance rate of 12% between core needle biopsies of axillary lymph node metastases and the primary tumors of mostly therapy-naïve breast cancer patients has been described by our group [53], strengthening the hypothesis that dissemination and transformation of receptor status are early events in tumor progression. This evidence concerns the gene ERBB2 and breast cancer.